Evotec SE has 7 Schedule 13D or 13G filings on record since 2025-10-29. 2 holders' latest filing reports 5% or more of ordinary shares, no par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Stated intent
Intent stated in Item 4 MAK Capital Fund LP
In furtherance of the Purpose of Transaction, the Reporting Persons sent a letter to the Issuer's Supervisory & Management Board, which letter is attached as Exhibit 2 to this Amendment 1.From Item 4 of the SCHEDULE 13D/A filed 2026-04-06
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Excalibur LuxCo SARL | 9.99% | 17,730,913 | SCHEDULE 13D/A, 2025-10-29 | 2025-10-27 |
| MAK Capital Fund LP | 7.1% | 12,681,898 | SCHEDULE 13D/A, 2026-05-01 | 2026-04-29 |
| Novo Holdings A/S | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Purpose of Transaction (Item 4)
MAK Capital Fund LP
SCHEDULE 13D A/2 Amendment 2 This Amendment 2 to the statement on Schedule 13D ("Amendment 2") to the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") by the MAK Capital Fund LP, a Bermuda limited partnership ("MAK Fund"), MAK Capital One L.L.C., a Delaware limited liability company ("MAK Capital"), as the investment manager of MAK Fund and Michael A. Kaufman, as Managing Member of MAK Capital (collectively with MAK Fund and MAK Capital, "MAK" and together MAK Fund and MAK Capital collectively the "Reporting Persons") on March 30, 2026 (the "Original Schedule 13D") and amendment number 1 thereto filed on April 6, 2026 ("Amendment 1" and together with this Amendment 2 and the Original Schedule 13D, "Schedule 13D") amends and supplements the Original Schedule 13D and Amendment 1 and relates to to the ordinary shares, no par value per share (the "Shares") of EVOTEC SE (the "Issuer") beneficially owned by the Reporting Persons. The principal executive offices of the Issuer are located at Essener Bogen 7, Hamburg, GERMANY , 22419. Except as set forth herein in this Amendment 2, the Schedule 13D is unmodified. In furtherance of the Purpose of Transaction, MAK Fund and Issuer signed a cooperation agreement on April 29, 2026. Under the terms, described further in the press release by Issuer filed with the SEC as Exhibit 99.1 to Issuer's Current Report on Form 6-K on April 30, 2026, Issuer will nominate Dr. Wolfgang Hofmann for election as an independent …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-01; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-29 | Excalibur LuxCo SARL | 9.99% | SCHEDULE 13D/A |
| 2025-11-14 | Novo Holdings A/S | 5.3% | SCHEDULE 13G/A |
| 2026-01-16 | MAK Capital Fund LP | 5.3% | SCHEDULE 13G |
| 2026-02-17 | Novo Holdings A/S | 0% | SCHEDULE 13G/A |
| 2026-03-30 | MAK Capital Fund LP | 7% | SCHEDULE 13D |
| 2026-04-06 | MAK Capital Fund LP intent stated | 7% | SCHEDULE 13D/A |
| 2026-05-01 | MAK Capital Fund LP | 7.1% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Evotec SE. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.